Compare BEN & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BEN | GH |
|---|---|---|
| Founded | 1947 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.5B | 14.8B |
| IPO Year | N/A | 2018 |
| Metric | BEN | GH |
|---|---|---|
| Price | $27.09 | $102.21 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 9 | 21 |
| Target Price | $25.89 | ★ $102.81 |
| AVG Volume (30 Days) | ★ 6.5M | 2.0M |
| Earning Date | 01-30-2026 | 02-19-2026 |
| Dividend Yield | ★ 4.87% | N/A |
| EPS Growth | ★ 64.88 | N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $8,846,200,000.00 | $902,569,000.00 |
| Revenue This Year | N/A | $35.23 |
| Revenue Next Year | $5.80 | $27.38 |
| P/E Ratio | $25.08 | ★ N/A |
| Revenue Growth | 1.23 | ★ 30.38 |
| 52 Week Low | $16.25 | $34.88 |
| 52 Week High | $28.32 | $120.74 |
| Indicator | BEN | GH |
|---|---|---|
| Relative Strength Index (RSI) | 57.40 | 42.58 |
| Support Level | $26.80 | $100.26 |
| Resistance Level | $28.32 | $107.69 |
| Average True Range (ATR) | 0.86 | 6.19 |
| MACD | 0.03 | -1.26 |
| Stochastic Oscillator | 62.77 | 20.87 |
Franklin Resources provides investment services for individual and institutional investors. At the end of July 2025, Franklin had $1.617 trillion in managed assets, composed primarily of equity (41%), fixed-income (27%), multi-asset/balanced (11%) funds, alternatives (16%) and money market funds (5%). Distribution tends to be weighted between retail investors (56% of AUM) and institutional accounts (41%), with high-net-worth clients accounting for the remainder. Franklin is one of the more global of the US-based asset managers we cover, with 31% of its assets under management invested in global/international strategies and just as much sourced from clients domiciled outside the United States.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.